Ligand Pharmaceuticals (LGND) EPS (Weighted Average and Diluted) (2010 - 2026)

Ligand Pharmaceuticals has disclosed EPS (Weighted Average and Diluted) across 17 years of filings, most recently posting -$0.67 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.67, up 69.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.43 (up 203.77% YoY), and the FY2025 annual result was $6.13, up 2886.36% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.67 for Q1 2026 at Ligand Pharmaceuticals, down from $2.18 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $5.68 in Q3 2025 to a low of -$2.88 in Q2 2024.
• The 5-year median for EPS (Weighted Average and Diluted) is $0.13 (2023), against an average of $0.45.
• Across the five-year window, EPS (Weighted Average and Diluted) sank 2315.38% in 2024 and surged 1556.41% in 2025, its largest moves.
• Ligand Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.86 in 2022, then soared by 219.77% to $1.03 in 2023, then tumbled by 263.11% to -$1.68 in 2024, then jumped by 229.76% to $2.18 in 2025, then tumbled by 130.73% to -$0.67 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.67 (Q1 2026), $2.18 (Q4 2025), and $5.68 (Q3 2025), per Business Quant data.